A vitamin found in eggs, milk, and leafy greens may be quietly protecting cancer cells from a form of death that scientists have spent years trying to unleash against tumors. Two studies published in May 2026 reveal that vitamin B2, also known as riboflavin, supplies the molecular raw material that keeps a critical defense protein intact inside cancer cells. When researchers cut off that supply, the protein self-destructed, and tumor cells that had resisted treatment became vulnerable to a single drug-like compound.
The findings, reported in Nature Cell Biology and Nature Structural and Molecular Biology, center on a process called ferroptosis, a type of cell death driven by iron and runaway damage to the fatty molecules in cell membranes. Unlike the orderly self-destruction most people associate with cell death, ferroptosis works more like a chemical fire: iron catalyzes chain reactions that shred membrane lipids until the cell collapses. For over a decade, cancer researchers have tried to trigger ferroptosis deliberately, hoping to burn through tumors that shrug off conventional therapies. The problem is that many cancer cells have built-in fire extinguishers.
The protein that keeps cancer cells fireproof
The most important of those fire extinguishers, at least for this story, is a protein called FSP1. First identified in 2019 by two independent research teams, FSP1 operates as a backup antioxidant system. Most cancer drugs that target lipid defenses go after a different protein, GPX4, which relies on the antioxidant glutathione. But FSP1 works through a separate mechanism: it recycles a molecule called coenzyme Q on the cell membrane, converting it into a form that neutralizes lipid radicals before they can spread. Because FSP1 and GPX4 operate on parallel tracks, knocking out one often fails to kill the cell. The other picks up the slack.
What the new studies show is that FSP1’s entire operation depends on a steady supply of FAD, a cofactor the body manufactures from vitamin B2. One team used CRISPR-based genetic screens and biochemical experiments to demonstrate that FAD physically binds to FSP1 and holds the protein in its functional shape. Without FAD, FSP1 becomes unstable. The cell’s quality-control machinery, specifically an E3 ubiquitin ligase, recognizes the misfolded protein, tags it for disposal, and feeds it into the proteasome, the cell’s internal shredder. The second team traced the upstream supply chain, showing that riboflavin uptake and its enzymatic conversion to FAD are the rate-limiting steps that determine how much functional FSP1 a cancer cell can maintain.
In practical terms, the researchers found that cancer cells deprived of riboflavin lost FSP1 protein rapidly. When those same cells were then exposed to a ferroptosis-inducing compound, they died at rates far higher than cells with normal vitamin B2 levels. The effect was striking because it required only a single compound to trigger death, not the combination therapies that ferroptosis research has increasingly relied on.
A different strategy: starving the shield instead of overpowering it
Previous efforts to disable FSP1 have focused on direct chemical inhibitors. One such molecule, known as iFSP1, was shown in 2023 to block FSP1’s enzymatic activity by competing for its active site. That approach works in cell culture, but active-site inhibitors face a familiar problem in drug development: cancer cells can mutate the target protein’s binding pocket, rendering the drug useless.
The riboflavin-targeting strategy sidesteps that issue. Instead of trying to outcompete FSP1 at its active site, it removes the cofactor the protein needs to exist at all. A protein that never folds correctly never reaches the membrane, never recycles coenzyme Q, and never suppresses ferroptosis. The researchers argue this approach could be harder for tumors to resist, because the dependency on FAD is baked into FSP1’s fundamental structure rather than confined to a single druggable pocket.
One compound that has drawn attention in this context is roseoflavin, a naturally occurring molecule produced by certain bacteria. Roseoflavin is structurally similar to riboflavin and is known to interfere with flavin metabolism in microbial systems, where it competes with riboflavin for cellular uptake. However, its activity has been characterized almost entirely in bacteria. Whether roseoflavin can reach mammalian tumors at effective concentrations, and what side effects it might cause in healthy tissue, remains untested in cancer models. It serves as proof that nature has already produced riboflavin antimetabolites, but it is not a drug candidate with clinical data behind it.
What the studies have not yet shown
Both studies were conducted in cell-based systems and biochemical assays, not in living animals or patients. No team has published data from mouse models treated with combined riboflavin restriction and ferroptosis inducers, and no clinical trials are underway or registered. That gap matters because riboflavin is an essential nutrient. Every cell in the body uses it, not just cancer cells. Systemic riboflavin depletion could damage healthy tissues in ways that cannot be predicted from laboratory dishes alone.
There are also species-specific complications. Structural studies of FSP1 inhibitors have revealed differences in how mouse and human versions of the protein respond to the same molecules. Results from rodent experiments, when they arrive, may not translate directly to human patients. And while FSP1 is known to be highly expressed in several aggressive cancer types, including certain lung, liver, and breast cancers, the new studies did not comprehensively map which tumor types would benefit most from a riboflavin-targeting approach.
No oncologists or clinical researchers have publicly commented on the feasibility of translating these findings into therapy. The mechanistic evidence is strong, published in top-tier journals with rigorous experimental controls, but the clinical path from mechanism to medicine remains entirely undefined.
Why this changes how researchers think about ferroptosis
For years, the ferroptosis field has operated on a straightforward logic: build compounds potent enough to overwhelm a cancer cell’s lipid-repair defenses, and the cell will die. That logic has produced dozens of experimental molecules, many of which work impressively in the lab but lose effectiveness in patients, partly because tumors activate backup systems like FSP1 that the drugs were never designed to address.
These new findings reframe the problem. Rather than engineering ever-stronger hammers, researchers now have a reason to look at the supply lines that keep the shield standing. Riboflavin metabolism was not previously on the radar as a cancer vulnerability. The discovery that it underpins FSP1 stability connects nutritional biochemistry to tumor survival in a way that opens genuinely new therapeutic territory.
Turning that insight into a treatment will require animal studies, toxicity profiling, pharmacokinetic work, and eventually clinical trials. None of that has been reported. But the science has clarified something that was previously invisible: the reason so many cancer cells survive ferroptosis is not just that they have a backup defense protein. It is that a common vitamin keeps that protein from falling apart. That understanding, even without a drug attached to it yet, reshapes the map that researchers will use to plan their next moves.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
